Drug Profile
Research programme: CRISPR/Cas9-enhanced CAR T-cell therapy - Beth Israel Deaconess Medical Center/Mustang Bio
Latest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator City of Hope National Medical Center
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for research development in Cancer in Israel (Parenteral)
- 01 Jan 2020 Harvard University terminates its licensing agreement with Mustang Bio
- 29 Jan 2018 Mustang Bio licensed chimeric antigen receptor engineered T-cells technology from City of Hope National Medical Center for the treatment of Cancer